UroGen Pharma, Ltd.

The US Food and Drug Administration is considering cancelling some advisory committee meetings in the wake of recent layoffs that have gutted the staff who plan and organize them. Review staff and pro

As UroGen prepares to bring a second drug to market later this year, the company is also expanding its early pipeline for long-term expansion. The company acquired a new early-stage asset, the next-ge

The US Food and Drug Administration is not scheduling new advisory committee meetings due to ongoing limits on agency communications, four sources told the Pink Sheet . Cancelling or postponing meeti

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp